Orphazyme is a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative rare diseases.
We are committed to providing relevant, accurate and timely information to investors and the financial community. Orphazyme is listed on Nasdaq Copenhagen (ORPHA) and Nasdaq US (ORPH).
| Date | Event Details |
|---|---|
| Summary Toggle 18/06/2021 |
Time: 8.00 AM CET
Confirmation Code: 2889481 United Kingdom, local........ +44 (0) 8444819752 Denmark, Copenhagen....... +45 32720417 France, Paris........................ +33 (0) 170700781 Netherlands, Amsterdam... +31 (0) 207956614 Sweden, Stockholm............ +46 (0) 856618467 Standard International....... +44 (0) 2071 928338 United States, New York +1 6467413167 |
| Summary Toggle 18/06/2021 |
Time: 2.00 PM CET
Confirmation Code: 9349928 United Kingdom, local........ +44 (0) 8444819752 Denmark, Copenhagen....... +45 32720417 France, Paris........................ +33 (0) 170700781 Netherlands, Amsterdam... +31 (0) 207956614 Sweden, Stockholm............ +46 (0) 856618467 Standard International....... +44 (0) 2071 928338 United States, New York +1 6467413167 |
| Summary Toggle 24/08/2021 |
Alerts are e-mailed to you whenever certain new company information is posted to this site.
Sign up here
